Logo of Biovectra, a part of Agilent, featuring stylized geometric design with purple and yellow elements against a black background.

360° VIRTUAL TOURS

360° VIRTUAL TOUR

Tour BIOVECTRA’s Microbial Fermentation Production Suites

Our microbial fermentation capabilities include both single-use and stainless-steel fermenters allowing BIOVECTRA to support your biologics projects at a large variety of scales. 

Tour our microbial fermentation suite to view the:

  • State-of-the-art 100 L and 1,000 L single-use fermenters
  • 3,000 L self-contained, closed, stainless steel fermenter
  • Two 17,000 L self-contained, closed, stainless steel fermenters – ideal for large-scale production
  • And more!

We offer a range of scale-up options for your recombinant proteins, plasmid DNA, antibody fragments, and other biologic molecules produced in microbial systems. 

Request Access to the 360 Tour

About Us

With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.

The image features the phrase "We Care" in white with a purple and yellow heart shape, representing a focus on empathy and support.

Contact Us

Toll Free: +1 (866) 883-2872
Phone: +1 (902) 566-9116
Fax: +1 (902) 628-2045

11 Aviation Avenue,
Charlottetown, PE, C1E 0A1
Canada

The image features the Biovectra logo, with stylized geometric shapes and bold text in purple and yellow.
Facebook Linkedin

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors